Eusebio Chiefari
Biographic Data
| ID | 7914550 |
|---|---|
| NAME | Eusebio Chiefari |
| GIVEN NAMES | Eusebio |
| FAMILY NAME | Chiefari |
| SIGNATURE | CHIEFARI E |
| AFFILIATIONS | Magna Graecia University |
| ORCID | 0000-0001-5329-3124 |
| VERIFIED | Yes |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 4 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2018 |
| LATEST PUBLICATION YEAR | 2020 |
| H-INDEX | 0 |
Potential Benefits and Harms of Novel Antidiabetic Drugs During Covid-19 Crisis
Patients with diabetes have been reported to have enhanced susceptibility to severe or fatal COVID-19 infections, including a high risk of being admitted to intensive care units with respiratory failure and septic complications. Given the global prevalence of diabetes, affecting over 450 million people worldwide and still on the rise, the emerging COVID-19 crisis poses a serious threat to an extremely large vulnerable population. However, the bro…
First Trimester Combined Test (FTCT) as a Predictor of Gestational Diabetes Mellitus
Background -The first trimester combined test (FTCT) is an effective screening tool to estimate the risk of fetal aneuploidy. It is obtained by the combination of maternal age, ultrasound fetal nuchal translucency (NT) measurement, and the maternal serum markers free β-human chorionic gonadotropin (β-hCG) and pregnancy-associated plasma protein A (PAPP-A). However, conflicting data have been reported about the association of FTCT, β-hCG, or PAPP-…
Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes
Background : Liraglutide is the first glucagon-like peptide-1 receptor agonist (GLP-1 RA) based on the human GLP-1 sequence, with potential weight loss benefits, approved for the treatment of type 2 diabetes (T2D) mellitus. Herein, we aimed to assess the 5-year effectiveness of Liraglutide in the management of weight and glycometabolic control in a Southern Italian cohort of overweight/obese T2D patients, who were naïve to GLP-1 RAs. Patients and…
Barriers to Postpartum Glucose Intolerance Screening in an Italian Population
Background : Gestational diabetes mellitus (GDM) is a strong risk factor for type 2 diabetes mellitus (T2D) and the postpartum period is crucial for early treatment in at-risk women. However, despite recommendations, only a fraction of women undergo a postpartum screening for glucose intolerance (ppOGTT). The present study aims to verify the reason(s) for poor adherence in our population. Research design and methods : This retrospective study inc…
No prominent works on this page.
Barriers to Postpartum Glucose Intolerance Screening in an Italian Population
Background : Gestational diabetes mellitus (GDM) is a strong risk factor for type 2 diabetes mellitus (T2D) and the postpartum period is crucial for early treatment in at-risk women. However, despite recommendations, only a fraction of women undergo a postpartum screening for glucose intolerance (ppOGTT). The present study aims to verify the reason(s) for poor adherence in our population. Research design and methods : This retrospective study inc…
First Trimester Combined Test (FTCT) as a Predictor of Gestational Diabetes Mellitus
Background -The first trimester combined test (FTCT) is an effective screening tool to estimate the risk of fetal aneuploidy. It is obtained by the combination of maternal age, ultrasound fetal nuchal translucency (NT) measurement, and the maternal serum markers free β-human chorionic gonadotropin (β-hCG) and pregnancy-associated plasma protein A (PAPP-A). However, conflicting data have been reported about the association of FTCT, β-hCG, or PAPP-…
Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes
Background : Liraglutide is the first glucagon-like peptide-1 receptor agonist (GLP-1 RA) based on the human GLP-1 sequence, with potential weight loss benefits, approved for the treatment of type 2 diabetes (T2D) mellitus. Herein, we aimed to assess the 5-year effectiveness of Liraglutide in the management of weight and glycometabolic control in a Southern Italian cohort of overweight/obese T2D patients, who were naïve to GLP-1 RAs. Patients and…
Potential Benefits and Harms of Novel Antidiabetic Drugs During Covid-19 Crisis
Patients with diabetes have been reported to have enhanced susceptibility to severe or fatal COVID-19 infections, including a high risk of being admitted to intensive care units with respiratory failure and septic complications. Given the global prevalence of diabetes, affecting over 450 million people worldwide and still on the rise, the emerging COVID-19 crisis poses a serious threat to an extremely large vulnerable population. However, the bro…
Medicine (4 works) · Diabetes mellitus (3 works) · Endocrinology (3 works) · Internal Medicine (3 works) · Diabetes Treatment and Management (2 works) · Environmental health (2 works) · Gestational Diabetes Research and Management (2 works) · Intensive care medicine (2 works) · Population (2 works) · Pregnancy and preeclampsia studies (2 works)